Cardlytics, Inc. (CDLX, Financial) has been the subject of recent analyst activity, with Lake Street's analyst, Jacob Stephan, maintaining a 'Hold' rating on the stock. This decision comes amid adjustments to their price target for the company.
On May 8, 2025, Jacob Stephan announced a reduction in the price target, lowering it from the previous $3.00 to $2.50. This change represents a significant decrease of 16.67% in the expected valuation of Cardlytics (CDLX, Financial).
The current price target adjustment underscores a cautious outlook for Cardlytics (CDLX, Financial), as reflected in the unchanged 'Hold' rating. Investors and those monitoring the performance of Cardlytics may find these updates pertinent in assessing the company's future prospects in the stock market.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 5 analysts, the average target price for Cardlytics Inc (CDLX, Financial) is $2.90 with a high estimate of $3.00 and a low estimate of $2.50. The average target implies an upside of 45.36% from the current price of $2.00. More detailed estimate data can be found on the Cardlytics Inc (CDLX) Forecast page.
Based on the consensus recommendation from 6 brokerage firms, Cardlytics Inc's (CDLX, Financial) average brokerage recommendation is currently 3.2, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Cardlytics Inc (CDLX, Financial) in one year is $5.35, suggesting a upside of 168.17% from the current price of $1.995. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Cardlytics Inc (CDLX) Summary page.
